![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Publisher's version)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
3MB |
| Item Type: | Review |
|---|---|
| Title: | Vaccine-associated enhanced disease and pathogenic human coronaviruses |
| Creators Name: | Gartlan, C., Tipton, T., Salguero, F.J., Sattentau, Q., Gorringe, A. and Carroll, M.W. |
| Abstract: | Vaccine-associated enhanced disease (VAED) is a difficult phenomenon to define and can be confused with vaccine failure. Using studies on respiratory syncytial virus (RSV) vaccination and dengue virus infection, we highlight known and theoretical mechanisms of VAED, including antibody-dependent enhancement (ADE), antibody-enhanced disease (AED) and Th2-mediated pathology. We also critically review the literature surrounding this phenomenon in pathogenic human coronaviruses, including MERS-CoV, SARS-CoV-1 and SARS-CoV-2. Poor quality histopathological data and a lack of consistency in defining severe pathology and VAED in preclinical studies of MERS-CoV and SARS-CoV-1 vaccines in particular make it difficult to interrogate potential cases of VAED. Fortuitously, there have been only few reports of mild VAED in SARS-CoV-2 vaccination in preclinical models and no observations in their clinical use. We describe the problem areas and discuss methods to improve the characterisation of VAED in the future. |
| Keywords: | Vaccine-Associated Enhanced Disease, COVID-19, SARS-CoV-2, Coronavirus, Vaccine, Enhancement, Safety |
| Source: | Frontiers in Immunology |
| ISSN: | 1664-3224 |
| Publisher: | Frontiers Media SA |
| Volume: | 13 |
| Page Range: | 882972 |
| Date: | 4 April 2022 |
| Official Publication: | https://doi.org/10.3389/fimmu.2022.882972 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
